What is Ionis Pharmaceuticals's tryngolza — revenue?

Ionis Pharmaceuticals (IONS) reported tryngolza — revenue of $4.57M in Q2 2026.

How has Ionis Pharmaceuticals's tryngolza — revenue changed year-over-year?

Ionis Pharmaceuticals's tryngolza — revenue decreased by 76.3% year-over-year, from $19.27M to $4.57M.

What does tryngolza — revenue mean?

This metric represents the net revenue recognized from the sale of the Tryngolza product, excluding any sales-based taxes collected from customers. It reflects the core commercial performance and market adoption of this specific therapeutic asset within the company's portfolio. This figure is critical for assessing the direct contribution of the product to the company's top-line growth and commercial viability.

Ionis Pharmaceuticals (IONS) Tryngolza — Revenue

Screener

Other product segments

Research And Development Revenue

$149.33M-57.2%

Collaborative Agreement Revenue

$133.14M-60.5%

Commercial

$118.62M+15.4%

Royalty

$75.96M+8.6%

Spinraza Royalties

$53.49M-1.6%

Wainus Royalties

$16.44M+57.8%

Wainua Joint Development Revenue

$16.19M+30.9%

Other Commercial

$11.53M-14.8%

Other Royalties

$6.04M+16.1%

Similar metrics at other companies

HRO

HROWOther Revenues — Revenue

$73K-15.1%

ORCLCloud Revenues — Revenue

$9.91B+47.1%

ORCLSoftware Revenues — Revenue

$6.82B-2.1%

OWLPerformance revenues — Revenue

$6.07M-3.9%

EAT

EATFranchise revenues — Revenue

$14.7M+21.5%

CNKOther Revenues — Revenue

$113.1M+18.2%

Other financials

Income statement

See full

Revenue$267.9M-40.7%

Gross profit$265.2M-40.8%

Operating income-$102.3M-173%

Net income-$114.6M-193%

EPS (diluted)-$0.69-199%

Balance sheet

See full

Cash & equivalents$350.1M+17.7%

Total debt$262.5M-67.0%

Total equity$439.7M-30.4%

Total assets$3.0B+0.3%

Cash flow

See full

Operating cash flow-$792.8M-426%

CapEx$16.1M+30.7%

Free cash flow-$814.6M-399%

Valuation

See full

Market cap$9.01B+38.9%

Enterprise value$8.92B+27.7%

P/S10.3×+3.4×

Profitability

See full

Gross margin98.2%-0.7pp

Operating margin-68%-234pp

Net margin-64.7%-299pp

FCF margin-77.4%+35.3pp

Returns & leverage

See full

Return on equity-105.5%+336pp

Debt / equity0.6×-0.7×

Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.

Filed: Jul 29, 2026, 5:05 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000874015-26-000251

Line item	Three Months Ended / June 30, 2026	Three Months Ended / June 30, 2025	Six Months Ended / June 30, 2026	Six Months Ended / June 30, 2025
Revenue:
Commercial revenue:
Product sales, net:
TRYNGOLZA sales, net	$$4,574	$19,273	$31,674	25,561
DAWNZERA sales, net	26,565	-	42,420	-
Total product sales, net	31,139	19,273	74,094	25,561
Royalty revenue:
SPINRAZA royalties	53,486	54,337	97,196	102,347

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ionis Pharmaceuticals's tryngolza — revenue?: Ionis Pharmaceuticals (IONS) reported tryngolza — revenue of $4.57M in Q2 2026.
How has Ionis Pharmaceuticals's tryngolza — revenue changed year-over-year?: Ionis Pharmaceuticals's tryngolza — revenue decreased by 76.3% year-over-year, from $19.27M to $4.57M.
What does tryngolza — revenue mean?: This metric represents the net revenue recognized from the sale of the Tryngolza product, excluding any sales-based taxes collected from customers. It reflects the core commercial performance and market adoption of this specific therapeutic asset within the company's portfolio. This figure is critical for assessing the direct contribution of the product to the company's top-line growth and commercial viability.